Table 1 Frequency and characteristics of baseline tophi for patients in the randomized trials
Characteristics | Pegloticase biweekly | Pegloticase monthly | Placebo |
|---|---|---|---|
(n= 85) | (n= 84) | (n= 43) | |
Patients with one or more baseline tophi, n (%) | 62 (73) | 64 (76) | 29 (67) |
Total number of measurable baseline tophi | 159 | 142 | 83 |
Median target area of measurable target tophi, mm2 (range) | 378 (25 to 4,080) | 377 (25 to 10,625) | 460 (30 to 6,230) |